Biologically Active Small Molecules

A multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC₅₀s = 2, 3, 6, 8, 84, and 59 nM, respectively) blocks VEGF-induced angiogenesis in the rat corneal

A multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC₅₀s = 2, 3, 6, 8, 84, and 59 nM, respectively) blocks VEGF-induced angiogenesis in the rat corneal

A selective Aurora kinase inhibitor (IC₅₀s = 5, 4, and 1 nM for Aurora A, B, and C, respectively) inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models.

A selective Aurora kinase inhibitor (IC₅₀s = 5, 4, and 1 nM for Aurora A, B, and C, respectively) inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models.

A selective Aurora kinase inhibitor (IC₅₀s = 5, 4, and 1 nM for Aurora A, B, and C, respectively) inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models.

A selective Aurora kinase inhibitor (IC₅₀s = 5, 4, and 1 nM for Aurora A, B, and C, respectively) inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models.

A competitive antagonist of capsaicin activation of the TRPV1 (IC₅₀s = 24.5 and 85.6 nM for human and rat, respectively) reverses thermal and mechanical hyperalgesia in a rat model of inflammatory pain.

A competitive antagonist of capsaicin activation of the TRPV1 (IC₅₀s = 24.5 and 85.6 nM for human and rat, respectively) reverses thermal and mechanical hyperalgesia in a rat model of inflammatory pain.

A competitive antagonist of capsaicin activation of the TRPV1 (IC₅₀s = 24.5 and 85.6 nM for human and rat, respectively) reverses thermal and mechanical hyperalgesia in a rat model of inflammatory pain.

A cell permeable inhibitor of PRMTs inhibits both yeast Hmt1p and human PRMT1 (IC₅₀ = 3.0 and 8.

A cell permeable inhibitor of PRMTs inhibits both yeast Hmt1p and human PRMT1 (IC₅₀ = 3.0 and 8.

A fungal metabolite that inhibits DGAT activity, preventing triacylglycerol formation (IC₅₀s = 10.2 and 15.5 &microM in rat liver microsomes and Raji cells, respectively.